Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

2021403 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 22, Issue 6, pp. 790-800

Field-Weighted Citation Impact: 27.92